Supplementary tables S1-S6
Supplementary table S1 Tumorigenic abilities of 20 th passage BCSC and their primary breast cancer cells in NOD/SCID mice. 
Constructs
Instructions regarding constructions of VISA plasmid, hTERT promoter-driven VISA nanoparticle delivery of miR-34a (TV-miR-34a) and hTERT promoter-driven VISA nanoparticle delivery of control (TV-miR-Ctrl) were described previously according to the standard molecular cloning protocol [2, 3] . The hTERT promoter was amplified by PCR using genomic DNA. GAL4-VP2 contains two VP16 activation C22ORF28-Ad (addition of C22ORF28) and C22ORF28-KD (knockdown of C22ORF28) were generated as previously described [4, 5] . For site-specific mutagenesis, we mutated the regions in the C22ORF28-3'UTR and LIN28A-3'UTR complementary to the seed sequence of miR-34a using the QuikChange II Site- , the mice were noninvasively imaged using the IVIS system to confirm tumor growth and then randomly assigned to one of three following treatment groups (10 mice per group): Each group of mice received 100µL
of DNA-liposome complexes that contained TV-miR-Ctrl liposomal complexes (10 μg qod), TV-miR-34a liposomal complexes (10 μg qod) or liposomal (Ctrl) alone.
The experiment was terminated on day 50. For observation of mice survival, all mice were evaluated for 80 days.
On 0, 2, 4, 6, 8 and 10 days after the injection, the mice were anesthetized and blood was collected by retro-orbital bleeding using a heparinized microcapillary tube.
The concentrations of serum alanine transaminase (ALT), aspartate transaminase (AST), blood urea nitrogen (BUN) and creatinine (Cr) were determined with an automatic analyzer (Roche Cobas Mira Plus; Roche, Mannheim, Germany). The test was repeated ten times.
The amount of cytokines (TNF-α, IL-6 and IFN-γ) in mouse sera was quantified using the cytometric bead array kit for mouse inflammatory cytokines (CBA; BD Biosciences) on a FACS Calibur cytometer equipped with Cell QuestPro and CBA software (Becton Dickinson). The test was repeated five times.
